Palvella Therapeutics (PVLA) Cash from Financing Activities (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Cash from Financing Activities data on file, last reported at $214.7 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 17964.48% year-over-year to $214.7 million in Q1 2026; TTM through Mar 2026 was $215.3 million, a 150.65% increase from a year earlier, with the FY2025 full-year figure at -$660000.0, down 100.76% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $214.7 million, up from -$49000.0 in the prior quarter.
• Over the last five years, Cash from Financing Activities for PVLA reached as high as $214.7 million in Q1 2026 and fell as low as -$14.8 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $22.4 million across 5 years, with a median of $315500.0 in 2022.
• Across the five-year window, Cash from Financing Activities tumbled 15993.55% in 2023 and jumped 17964.48% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $93000.0 in 2022, then tumbled by 15993.55% to -$14.8 million in 2023, then soared by 605.95% to $74.8 million in 2024, then tumbled by 100.07% to -$49000.0 in 2025, then surged by 438326.53% to $214.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $214.7 million in Q1 2026, -$49000.0 in Q4 2025, and $242000.0 in Q3 2025.